A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB)
To see if DMX-200 reduces proteinuria and slows the loss of kidney function when taken at the same time as an ARB in patients with focal segmental glomerulosclerosis (FSGS)
Why this Research Matters
There is an option to join an open-label period following the randomized 2-year period. In the open-label period, all subjects will take the study medication, repagermanium.
Who can Participate
Diagnosis of FSGS and receiving an ARB (or willing to begin ARB) PCR grreater than 1.5 g/g; eGFR between 25 and 120 mL/min/1.73 m2; primary FSGS diagnosis confirmed with biopsy.
Study ID
Protocol Number: 25-0349
Meet the Team
Principal Investigator